{
    "clinical_study": {
        "@rank": "23251", 
        "acronym": "PRECLOP", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "description": "Will include patients with PRU values above the optimal cut-off value determined by ROC analysis"
            }, 
            {
                "arm_group_label": "Group B", 
                "description": "Will include patients with PRU values below the optimal cut-off value determined by ROC analysis."
            }
        ], 
        "brief_summary": {
            "textblock": "Antiplatelet therapy with clopidogrel is recommended following peripheral endovascular\n      procedures. The clinical significance of an inadequate response to clopidogrel following\n      percutaneous coronary interventions has been recently recognized.This study was designed to\n      investigate platelet responsiveness to Clopidogrel following endovascular therapy of\n      peripheral arterial disease using the VerifyNow P2Y12 point-of-care testing and to determine\n      the optimal P2Y12 reactive unites (PRU) cut-off value of platelet inhibition influencing\n      outcomes of infrainguinal angioplasty or stenting in patients receiving clopidogrel\n      antiplatelet therapy."
        }, 
        "brief_title": "High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influence of PRU Values on Primary Outcome", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients suffering from Rutherford 3-6 stage of peripheral arterial disease scheduled\n             to undergo femoropopliteal or and infrapopliteal angioplasty or stenting.\n\n          -  Patients receiving Clopidogrel per os 75 mg daily at least 1 month prior and 1 year\n             after the procedure.\n\n        Exclusion Criteria:\n\n          -  Acute limb ischemia\n\n          -  Coagulation disorders\n\n          -  Known allergy to clopidogrel\n\n          -  Failure to comply with the antiplatelet treatment protocol\n\n          -  Aortoiliac disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Consecutive patient sampling of all patients undergoing pre-scheduled infrainguinal\n        angioplasty or stenting due to symptomatic arterial disease in our Department from January\n        2010, treated with clopidogrel 75 mg daily."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744613", 
            "org_study_id": "822"
        }, 
        "intervention_browse": {
            "mesh_term": "Clopidogrel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Clopidogrel", 
            "platelet inhibition", 
            "antiplatelet therapy", 
            "peripheral arterial disease", 
            "endovascular treatment", 
            "angioplasty", 
            "stenting"
        ], 
        "lastchanged_date": "January 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rion", 
                    "country": "Greece", 
                    "state": "Achaia", 
                    "zip": "26500"
                }, 
                "name": "Patras University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_groups": "2", 
        "official_title": "Clinical Impact of High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures. The PRECLOP Study (Platelet REsponsiveness to CLOpidogrel Treatment After Peripheral Angioplasty or Stenting)", 
        "overall_official": [
            {
                "affiliation": "Patras University Hospital", 
                "last_name": "Dimitrios Siablis, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Patras University Hospital", 
                "last_name": "Dimitrios Karnabatidis, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Patras University Hospital", 
                "last_name": "Stavros Spiliopoulos, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Patras University Hospital", 
                "last_name": "Georgios Pastromas, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Patras University Hospital", 
                "last_name": "Konstantinos Katsanos, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Greece: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "12 months freedom from all causes of death, stroke, index limb amputation, non pre-scheduled minor amputation, index limb bypass surgery and target vessel recanalization (TVR)stratified according to PRU values distribution", 
                "measure": "Major event-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Optimal P2Y12 reactive unites (PRU) cut-off value of platelet inhibition measured with VerifyNow P2Y12 assay point-of-care testing, influencing the 12 months primary outcome of major event-free survival estimated by ROC analysis", 
                "measure": "Optimal P2Y12 reactive unites (PRU) cut-off value of platelet inhibition", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744613"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Patras", 
            "investigator_full_name": "SIABLIS DIMITRIOS", 
            "investigator_title": "Dimitrios Siablis, Professor of Radiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Positive and negative predictive value of PRU measurement with regard to the primary outcome of major event-free survival", 
                "measure": "Positive and negative predictive value of PRU testing", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "12-months bleeding rate including intracranial hemorrhage and puncture related pseudoaneurysm stratified according to PRU values", 
                "measure": "Bleeding rate", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University of Patras", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Patras", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "January 2013"
    }
}